1. Title (length 26):
Effects of Hormone Changes

2. Writing Group (list individual with lead responsibility first):
(lead) Folsom           Shahar              Patsch
    Nabulsi              McGovern
    White                Carpenter

3. Timeline:
Data analysis can begin as soon as Visit 2 data are complete. Draft manuscript four months later.

4. Rationale:
Our recent ARIC paper in the *New England Journal of Medicine* showed cross-sectional associations of physiologic factors with estrogen replacement versus estrogen plus progestin replacement. Visit 1 to Visit 2 data offers an opportunity to look at changes in lipids, blood pressure, and glucose with replacement therapy changes. (Unfortunately hemostasis specimens aren't available at Visit 2).

5. Main Hypothesis:
We expect the longitudinal results to be consistent with the cross-sectional results. That is, in the change data, hormone use will be associated with better physiologic profiles than non-use; users of estrogen plus progestin will have lower triglycerides than non-users. (If results on lipids look promising, it may be worthwhile to thaw out some Visit 2 blood specimens to do hemostasis measurements on a sample of those who changed hormone status.)

6. Data (variables, time window, source, inclusions/exclusions):
Visit 1 and 2 data sets. Dependent variables - change in lipids, glucose, blood pressure. Independent variables - change in hormone status, initial risk factor level. Covariates - changes in weight and in other determinants of the dependent variables.